Stryker's Deal For Spine Device Maker Vexim Rounds Up Ortho M&A Trilogy

It's been a busy week for ortho M&A activity, with three key sector players cutting deals. Smith & Nephew's agreement to buy Rotation Medical kick-started the week, then two more deals followed in succession, with Exactech announcing it was to be acquired by private equity firm TPG Capital and Stryker saying it will acquire a majority control of Vexim, a French spinal device maker.

It's been a busy week for M&A in the orthopedics space, with the announcement of three strategic deals in succession.

The most recent transaction came on Oct. 24, when Stryker Corp. announced it was acquiring French spinal device maker...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Orthopedics

More from Device Area

  • Owkin Teams With AstraZeneca To Develop AI-Based Breast Cancer Prescreening Tool

     

    Biopharmaceutical giant AstraZeneca has partnered with start-up “unicorn” Owkin to develop an AI-powered tool to prescreen for gBRCA mutations on the basis of morphological features in digitized pathology slides. Built on extensive, high-quality data sourced from the France-based PortrAIt consortium, the AI will help to prioritize patients for further testing, streamlining the diagnostic process, Owkin says.

  • Route 92 To Drive FreeClimb Neurointervention Sales With Extended Series F Funding

     

    An additional $50m brings the neurovascular intervention specialist’s total Series F funding to $82m. Route 92 says it will use the capital to build its sales and support teams and pursue regulatory authorizations around the globe for its FreeClimb portfolio while advancing its SUMMIT MAX clinical trial for the investigational Monopoint Reperfusion System.

  • TRiCares Initiates EU Pivotal Study For Topaz Tricuspid Valve Replacement

     

    TRiCares announced first implantation of the Topaz transfemoral tricuspid heart valve replacement system as part of the company’s EU pivotal study. If all goes to plan, the device will compete with Edwards’ Evoque system. The announcement follows the company’s $50m series D funding raise in July.